, Nov. 14, 2019
/PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a global business research and consulting firm. WuXi AppTec was awarded this honor for the third consecutive year.
The Frost & Sullivan Best Practices Award series honors companies that have pushed the boundaries of excellence in the areas of leadership, technological innovation, customer service, and business development. Frost & Sullivan recognized WuXi AppTec as a reliable and reputable participant in the global healthcare industry, providing cutting-edge drug discovery and development solutions alongside data management and analytics services. With a full range of services, WuXi AppTec is able to provide tailor-made drug development solutions to meet clients' varying needs.
"WuXi AppTec is one of the industry's leading providers that achieves consistent year-on-year growth by aligning its integrated R&D services with changing market dynamics," said Aarti Chitale
, senior research analyst from Frost & Sullivan. "The company's broad industry coverage and strength across early-stage drug discovery have enabled it to maintain and expand its client base across several countries. WuXi AppTec offers cost-effective strategic solutions, allowing the service provider to adhere to industry best practices and deliver timely results in drug discovery and development."
"Thanks Frost & Sullivan for recognizing WuXi's global platform," said Dr. Ge Li
, chairman and CEO of WuXi AppTec. "By providing open-access capabilities and technology, we are committed to enabling our customers worldwide to advance discoveries and bring better medicines to patients far faster."
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need and to realize our vision that "every drug can be made and every disease can be treated."
View original content:http://www.prnewswire.com/news-releases/wuxi-apptec-receives-2019-global-integrated-drug-development-competitive-strategy-innovation--leadership-award-from-frost--sullivan-300957317.html
SOURCE WuXi AppTec